These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 36091028)

  • 1. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
    Xiao X; Wang Y; Zou Z; Yang Y; Wang X; Xin X; Tu S; Li Y
    Front Immunol; 2022; 13():954235. PubMed ID: 36091028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
    Ruella M; Korell F; Porazzi P; Maus MV
    Nat Rev Drug Discov; 2023 Dec; 22(12):976-995. PubMed ID: 37907724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of bone marrow microenvironment on CAR-T efficacy in haematologic malignancies.
    Gao D; Hong F; He A
    Scand J Immunol; 2023 Aug; 98(2):e13273. PubMed ID: 39007933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.
    Dreyzin A; Rankin AW; Luciani K; Gavrilova T; Shah NN
    Expert Rev Clin Immunol; 2024 Jul; 20(7):745-763. PubMed ID: 38739466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
    Huang J; Huang X; Huang J
    Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review.
    Pérez-Moreno MA; Ciudad-Gutiérrez P; Jaramillo-Ruiz D; Reguera-Ortega JL; Abdel-Kader Martín L; Flores-Moreno S
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
    Sun W; Liang AB; Huang H; Huang XJ
    Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
    Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
    Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies.
    Huang Y; Qin Y; He Y; Qiu D; Zheng Y; Wei J; Zhang L; Yang DH; Li Y
    Drug Resist Updat; 2024 May; 74():101082. PubMed ID: 38569225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
    Zhou D; Zhu X; Xiao Y
    Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
    Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
    BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
    Mavi AK; Gaur S; Gaur G; Babita ; Kumar N; Kumar U
    Cell Signal; 2023 May; 105():110638. PubMed ID: 36822565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel technologies for improving the safety and efficacy of CAR-T cell therapy.
    Ohta K; Sakoda Y; Tamada K
    Int J Hematol; 2023 May; 117(5):647-651. PubMed ID: 36309630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
    Guo Z; Tu S; Yu S; Wu L; Pan W; Chang N; Zhou X; Song C; Li Y; He Y
    Cancer Sci; 2021 Apr; 112(4):1357-1368. PubMed ID: 33416209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
    Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
    Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.